Clarius Group’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
Other funds holding LYEL
MC
OP
Clarius Group's LYEL Position: Q4 2025 in Review
Clarius Group held its Lyell Immunopharma (LYEL) position steady in Q4 2025 at 19,958 shares worth $614K. The position accounts for 0.04% of the portfolio, ranked #174.
Clarius Group first reported a position in LYEL in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.27M in Q2 2023. 68 funds tracked by Wall St. Rank hold LYEL as of Q4 2025.
- Clarius Group held 19,958 shares of Lyell Immunopharma worth $614K as of Q4 2025.
- Clarius Group left its Lyell Immunopharma share count unchanged in Q4 2025.
- Lyell Immunopharma made up 0.04% of Clarius Group's portfolio in Q4 2025, its #174 holding.
- Clarius Group first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 17 quarters since.
- Clarius Group's Lyell Immunopharma position peaked at $1.27M in Q2 2023.
- 68 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2025.
Based on Clarius Group's 13F filing for Q4 2025, filed 14 Jan 2026.